Can You Take Phenytoin and Warfarin Together? What You Need to Know

Phenytoin and warfarin can be prescribed together, but this combination requires close monitoring because phenytoin can reduce warfarin's effectiveness by increasing its metabolism. Patients taking both medications need regular INR (International Normalized Ratio) blood tests and may require warfarin dose adjustments to maintain therapeutic anticoagulation. Any change to phenytoin dosing should prompt immediate communication with your anticoagulation provider.

What the FDA Says About This Combination

The FDA labeling for warfarin (Coumadin) explicitly lists anticonvulsants, including phenytoin, as drugs that can interact with warfarin. The warfarin label classifies this as a significant interaction that can result in decreased warfarin effectiveness. Similarly, phenytoin's labeling identifies warfarin among the many drugs it can interact with through enzyme induction.

While neither drug's label uses the strongest warning language (black box), the interaction is well-documented enough that both medications carry precautions against concurrent use without careful management. The FDA recommendation is not to avoid combining these drugs, but rather to recognize that enhanced monitoring and possible dose adjustment are essential.

The severity of this interaction is classified as moderate to significant in clinical practice guidelines. Unlike some benign interactions that require no action, this one demands active pharmacological management and patient awareness.

How This Interaction Works: The Pharmacological Mechanism

The interaction between phenytoin and warfarin occurs primarily through a mechanism called enzyme induction. Phenytoin is a potent inducer of cytochrome P450 enzymes, particularly CYP2C9, CYP3A4, and CYP2C19. These enzymes are responsible for metabolizing warfarin in the liver.

When phenytoin is present, it increases the activity and expression of these enzymes. This means the liver breaks down warfarin more rapidly than it normally would. As a result, warfarin's concentration in the bloodstream drops, reducing its anticoagulant effect. This decreased effect translates to a lower INR—meaning the blood is less inhibited from clotting.

Warfarin itself is metabolized by CYP2C9 (for the S-enantiomer, which is more potent) and CYP3A4 and CYP1A2 (for the R-enantiomer). Phenytoin's broad inducing capability affects multiple pathways, making the interaction particularly robust.

Additionally, phenytoin may interfere with the synthesis of vitamin K-dependent clotting factors through separate mechanisms. However, the predominant clinical effect is enzyme induction leading to accelerated warfarin clearance.

This interaction is not instantaneous. It typically takes 7–10 days for phenytoin induction to reach full effect, and it may take a similar timeframe to reverse if phenytoin is discontinued. This delayed onset is clinically important because patients may not notice a problem immediately, and warfarin doses adjusted for concurrent phenytoin use may become excessive once phenytoin is stopped.

Who Is Most at Risk

Certain patient populations face heightened risk with this combination:

• Patients with atrial fibrillation on anticoagulation: These patients require reliable anticoagulation to prevent stroke. Loss of warfarin efficacy due to phenytoin could lead to clot formation.
• Post-thrombotic event patients: Those who have suffered a pulmonary embolism or deep vein thrombosis and are on warfarin for secondary prevention cannot tolerate reduced anticoagulation.
• Mechanical valve recipients: Patients with mechanical heart valves require stable warfarin therapy. Any reduction in INR puts them at risk for valve thrombosis, a medical emergency.
• Patients with hepatic impairment: The liver is where both drugs are metabolized. Impaired hepatic function makes predicting the net effect more difficult.
• Elderly patients: Older adults often have reduced drug metabolism and are more sensitive to anticoagulation changes.
• Patients taking high-dose phenytoin: Higher phenytoin doses produce stronger enzyme induction, making the interaction more pronounced.
• Those with poor medication adherence: Inconsistent phenytoin dosing makes stable warfarin dosing nearly impossible to achieve.

Patients taking other CYP2C9 inducers or inhibitors face compounded complexity, as the net metabolic effect becomes harder to predict.

Clinical Scenario 1: Atrial Fibrillation with New-Onset Seizures

A 72-year-old woman with a history of atrial fibrillation has been stable on warfarin 5 mg daily for three years, maintaining an INR target of 2.0–3.0. She presents to her neurologist with new-onset seizures and is started on phenytoin 300 mg daily (in divided doses). Her INR at baseline is 2.4, well within range.

One week after starting phenytoin, her cardiologist routinely checks INR as part of follow-up and finds it has dropped to 1.8. Over the next two weeks, as phenytoin induction reaches full effect, her INR continues declining to 1.4. At this point, she is subtherapeutic and at increased risk for atrial fibrillation-related stroke.

Had there been no communication between her neurologist and cardiologist, this drop might have gone unnoticed for weeks. Instead, because both providers were aware of the interaction, warfarin was increased to 7 mg daily. Her INR stabilizes at 2.3 after the adjustment.

Six months later, the seizures are controlled and phenytoin is gradually discontinued. Within 10 days of stopping phenytoin, her INR rises to 3.2, now supratherapeutic. The accumulated warfarin dose (which was necessary while she was on phenytoin) is now excessive. Warfarin must be reduced back to 5 mg daily, and her INR is re-stabilized at 2.1.

This scenario illustrates why close coordination and frequent monitoring are essential.

Clinical Scenario 2: Post-Pulmonary Embolism with Temporal Lobe Epilepsy

A 45-year-old man suffered a pulmonary embolism after orthopedic surgery and was started on warfarin for a planned 6–12 month course. He also has temporal lobe epilepsy, well-controlled for years on phenytoin 400 mg daily. His INR has been stable at 2.5 for the past three months.

He follows up with his anticoagulation clinic and everything appears well controlled. However, the combination is working—his high warfarin dose (8 mg daily) is necessary precisely because phenytoin is present. This equilibrium is maintained as long as phenytoin dosing remains consistent.

One month later, the patient's neurologist decides to trial a newer anticonvulsant (levetiracetam) as an adjunct and begins tapering phenytoin. The patient is instructed to reduce phenytoin by 100 mg per week. By week two of the taper, phenytoin levels fall and CYP2C9 induction begins to wane. His INR climbs from 2.5 to 3.0, then to 3.6—approaching levels associated with increased bleeding risk.

Fortunately, the anticoagulation clinic is checking INR every two weeks and catches the rise. Warfarin is reduced preemptively from 8 mg to 6.5 mg daily. By the time phenytoin is fully stopped, his INR stabilizes at 2.4 with the reduced warfarin dose.

This scenario shows why any change to seizure medication dosing must be communicated to the anticoagulation team.

What to Do: Practical Management Guidance

If you are already on both drugs: Do not stop either medication without talking to your doctor. Ensure that your anticoagulation provider (cardiologist, internist, or anticoagulation clinic) and your neurologist are aware you are taking both. Aim for INR checks every 2–4 weeks until stable, then every 4–12 weeks depending on stability and guidelines.

If starting phenytoin while on warfarin: Inform your prescribing neurologist that you are on warfarin. Ask them to communicate with your anticoagulation provider. Expect your warfarin dose to need adjustment upward. Plan for INR checks 7–10 days after starting phenytoin, then regularly thereafter.

If starting warfarin while on phenytoin: Your anticoagulation provider should be aware of the phenytoin. Expect higher warfarin doses may be needed. Do not adjust warfarin on your own based on prior experience; this situation is different.

If changing phenytoin dose or stopping it: Immediately notify your anticoagulation provider. Do not make warfarin adjustments yourself. Wait 7–10 days after any phenytoin change before expecting INR to stabilize, then check INR and allow your doctor to adjust warfarin if needed.

Medication list: Keep a complete, up-to-date list of all your medications and share it with every provider you see. Use a pharmacy that maintains integrated records so the pharmacist can flag this interaction.

Consider alternative anticonvulsants: If you are newly diagnosed with seizures and already on warfarin, ask your neurologist whether newer anticonvulsants (levetiracetam, lamotrigine, lacosamide) might be preferable, as they cause less enzyme induction. However, this decision should be made based on seizure type and individual factors—phenytoin is still appropriate for many patients.

When to Call Your Doctor or Pharmacist

Contact your doctor immediately if you experience:

• Unusual bruising or bleeding (nosebleeds, bleeding gums, blood in urine or stool)
• Bleeding from a minor cut that doesn't stop after 10–15 minutes
• Signs of blood clots: sudden leg swelling, calf pain, shortness of breath, or chest pain
• Unexplained severe headache
• Any change to your phenytoin dose or timing
• Starting or stopping any new medication (including over-the-counter drugs, supplements, or herbal products)
• Significant changes in diet, especially vitamin K intake (leafy greens affect warfarin)
• Illness or fever that might affect medication metabolism

Contact your pharmacist before filling any new prescription, and always mention that you are taking both phenytoin and warfarin.

Key Takeaways

• Phenytoin induces the metabolism of warfarin: Phenytoin increases liver enzyme activity (CYP2C9 and others), causing warfarin to be broken down more rapidly and reducing its anticoagulant effect.
• This combination requires monitoring, not avoidance: The two drugs can be used together safely with appropriate INR monitoring and dose adjustment. This is a manageable interaction, not a contraindication.
• INR testing is essential: Regular INR checks (every 2–4 weeks initially, then as directed) are mandatory. Warfarin doses will almost certainly need to be higher when phenytoin is present.
• Timing matters: Full induction takes 7–10 days to develop and a similar timeframe to reverse. Never adjust warfarin immediately; allow time for the interaction to equilibrate before checking INR.
• Communication is critical: All your prescribers must know you are taking both medications. Any change to either drug requires notification to the other provider.

Sources

• FDA Drug Labeling for Warfarin Sodium (Coumadin): https://www.accessdata.fda.gov/cder/foi/label/2011/009218s106lbl.pdf (or via OpenFDA: https://open.fda.gov/)
• FDA Drug Labeling for Phenytoin (Dilantin): Available through FDA OpenFDA database at https://open.fda.gov/
• Zanger UM, Schwab M. Cytochrome P450 and drug metabolism. Nature Reviews Drug Discovery. 2013;12(9):735–747. PMID: 23899423
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Archives of Internal Medicine. 2005;165(10):1095–1106. PMID: 15911722
• National Institutes of Health, PubChem: Phenytoin compound summary https://pubchem.ncbi.nlm.nih.gov/compound/5743
• National Institutes of Health, PubChem: Warfarin compound summary https://pubchem.ncbi.nlm.nih.gov/compound/54385370
• National Library of Medicine, MedlinePlus: Drug Interactions Information https://medlineplus.gov/druginteractions/

Related Drug Interactions

If you're taking phenytoin or warfarin, you may want to review other important interactions. Learn more about warfarin and aspirin interaction, or explore phenytoin and methotrexate interaction. You can also check warfarin and ibuprofen interaction for another common pairing that requires caution.

Get Your Complete Medication Interaction Check

This article covers the phenytoin-warfarin interaction in detail, but it represents just two drugs. Most patients take multiple medications, supplements, and over-the-counter products. The cumulative effect of all these interactions can be significant and unpredictable. To ensure you're not at risk from any hidden interaction in your complete medication regimen, enter your full drug list at checkdruginteractions.com. Our comprehensive database, powered by over 250,000 FDA drug labels, will identify every known interaction and provide you with actionable guidance to discuss with your pharmacist or doctor. Your safety depends on knowing the whole picture—not just isolated pairs.